Lansoprazole 15 Mg Gastro-Resistant Capsules
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Lansoprazole 15 mg Gastro-resistant Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains lansoprazole, 15 mg For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Gastro-resistant capsule, hard.
Size 3, white cap marked with ‘L’ and white body marked with ‘15’, containing white to beige gastro-resistant micropellets.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
• Treatment of duodenal and gastric ulcer
• Treatment of reflux oesophagitis
• Prophylaxis of reflux oesophagitis
• Eradication of Helicobacter pylori (H.pylori) concurrently given with appropriate antibiotic therapy for treatment of H.pylori-associated ulcers.
• Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment.
• Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk (see section 4.2) requiring continued therapy
• Symptomatic gastroesophageal reflux disease Zollinger-Ellison Syndrome
4.2 Posology and method of administration
For optimal effect, lansoprazole should be taken once daily in the morning, except when used for H. pylori eradication when treatment should be twice a day, once in the morning and once in the evening. Lansoprazole should be taken at least 30 minutes before food (see section 5.2). The capsules should be swallowed whole. Do not crush or chew.
Treatment of duodenal ulcer:
The recommended dose is 30 mg once daily for 2 weeks. In patients not fully healed within this time, the medication is continued at the same dose for another two weeks.
Treatment of gastric ulcer:
The recommended dose is 30 mg once daily for 4 weeks. The ulcer usually heals within 4 weeks, but in patients not fully healed within this time, the medication may be continued at the same dose for another 4 weeks.
Reflux oesophagitis:
The recommended dose is 30 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.
Prophylaxis of reflux oesophagitis:
15 mg once daily. The dose may be increased up to 30 mg daily as necessary. Eradication of Helicobacter _ pylori:
When selecting appropriate combination therapy consideration should be given to official local guidance regarding bacterial resistance, duration of treatment, (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.
The recommended dose is 30 mg of lansoprazole twice daily for 7 days in combination with one of the following:
clarithromycin 250-500 mg twice daily + amoxicillin 1 g twice daily clarithromycin 250 mg twice daily + metronidazole 400-500 mg twice daily
The H. pylori eradication results obtained when clarithromycin is combined with either amoxicillin or metronidazole give rates of up to 90%, when used in combination with lansoprazole.
Six months after successful eradication treatment, the risk of re infection is low and relapse is therefore unlikely.
Use of a regimen including lansoprazole 30 mg twice daily, amoxicillin 1 g twice daily and metronidazole 400-500 mg twice daily has also been examined. Lower eradication rates were seen using this combination than in regimens involving clarithromycin. It may be suitable for those who are unable to take clarithromycin as part of an eradication therapy, when local resistance rates to metronidazole are low.
Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment:
30 mg once daily for four weeks. In patients not fully healed the treatment may be continued for another four weeks. For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/or a higher dose should probably be used.
Prophylaxis of NSAID associated gastric and duodenal ulcers in patients at risk (such as age 65 or history of gastric or duodenal ulcer) requiring prolonged NSAID treatment:
15 mg once daily. If the treatment fails the dose 30 mg once daily should be used.
Symptomatic gastro-oesophageal reflux disease:
The recommended dose is 15 mg or 30 mg daily. Relief of symptoms is obtained rapidly. Individual adjustment of dosage should be considered. If the symptoms are not relieved within 4 weeks with a daily dose of 30 mg, further examinations are recommended.
Zollinger-Ellison syndrome:
The recommended initial dose is 60 mg once daily. The dose should be individually adjusted and the treatment should be continued for as long as necessary. Daily doses of up to 180 mg have been used. If the required daily dose exceeds 120 mg, it should be given in two divided doses.
Impaired hepatic or renal function:
There is no need for a dose adjustment in patients with impaired renal function.
Patients with moderate or severe liver disease should be kept under regular supervision and a 50% reduction of the daily dose is recommended (see section 4.4 and 5.2).
Elderly: Due to reduced clearance of lansoprazole in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 30 mg should not be exceeded in the elderly unless there are compelling clinical indications.
Children: The use of lansoprazole is not recommended in children as clinical data are limited (see section 5.2). Treatment of small children below one year
of age should be avoided as available data have not shown beneficial effects in the treatment of gastro-oesophageal reflux disease
4.3 Contraindications
• The use of lansoprazole is contra-indicated in patients with a history of hypersensitivity to lansoprazole or any of the ingredients of lansoprazole capsules.
• Lansoprazole should not be administered with atazanavir (see section 4.5)
4.4 Special warnings and precautions for use
In common with other anti-ulcer therapies, the possibility of malignant gastric tumour should
be excluded when gastric ulcer is suspected, as symptoms may be alleviated and
diagnosis
delayed.
Similarly, the possibility of serious underlying disease such as malignancy should be excluded before treatment for dyspepsia commences, particularly in patients of middle age or
older who have new or recently changed dyspeptic symptoms.
Lansoprazole should be used with caution in patients with moderate and severe hepatic
dysfunction (see section 4.2 and 5.2).
Decreased gastric acidity due to lansoprazole may be expected to increase gastric counts of
bacteria normally present in the gastrointestinal tract. Treatment with lansoprazole may lead
to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter.
In patients suffering from gastro-duodenal ulcers, the possibility of H.pylori infection as an
etiological factor should be considered.
If lansoprazole is used in combination with antibiotics for eradication therapy of H.pylori,
then the instructions for the use of these antibiotics should also be followed.
Because of limited safety data for patients on maintenance treatment for longer than 1 year,
regular review of the treatment and a thorough risk/benefit assessment should regularly be
performed in these patients.
Very rarely cases of colitis have been reported in patients taking lansoprazole. Therefore, in
the case of severe and/or persistent diarrhoea, discontinuation of therapy should be considered.
Hypomagnesaemia
Severe hypomagnesaemia has been reported in patients treated with PPIs like lansoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.
For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.
Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.
The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID
treatment should be restricted to high risk patients (e.g. previous gastrointestinal bleeding,
perforation or ulcer, advanced age, concomitant use of medication known to increase the
likelihood of upper GI adverse events [e.g. corticosteroids or anticoagulants], the presence of
a serious co-morbidity factor or the prolonged use of NSAID maximum recommended doses).
This product contains sucrose and therefore patients with rare hereditary problems of fructose
intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency
should not
take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Effects of lansoprazole on other drugs
Medicinal products with pH dependent absorption
Lansoprazole may interfere with the absorption of drugs where gastric pH is critical to bioavailability.
Atazanavir:
A study has shown that co-administration of lansoprazole (60 mg once daily) with atazanavir 400 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 90% decrease in AUC and Cmax). Lansoprazole should not be co-administered with atazanavir (see section 4.3).
Ketoconazole and itraconazole:
The absorption of ketoconazole and itraconazole from the gastrointestinal tract is enhanced by the presence of gastric acid. Administration of lansoprazole may result in sub-therapeutic concentrations of ketoconazole and itraconazole and the combination should be avoided.
Digoxin:
Co-administration of lansoprazole and digoxin may lead to increased digoxin plasma levels. The plasma levels of digoxin should therefore be monitored and the dose of digoxin adjusted if necessary when initiating and ending lansoprazole treatment.
Medicinal products metabolised by P450 enzymes
Lansoprazole may increase plasma concentrations of drugs that are metabolised by CYP3A4. Caution is advised when combining lansoprazole with drugs which are metabolised by this enzyme and have a narrow therapeutic window.
Theophylline:
Lansoprazole reduces the plasma concentration of theophylline, which may decrease the expected clinical effect at the dose. Caution is advised when combining the two drugs.
Tacrolimus:
Co-administration of lansoprazole increases the plasma concentrations of tacrolimus (a CYP3A and P-gp substrate). Lansoprazole exposure increased the mean exposure of tacrolimus by up to 81%. Monitoring of tacrolimus plasma concentrations is advised when concomitant treatment with lanzoprazole is initiated or ended.
Medicinal products transported by P-glycoprotein
Lansoprazole has been observed to inhibit the transport protein, P-glycoprotein (P-gp) in vitro. The clinical relevance of this is unknown.
Effects of other drugs on lansoprazole
Drugs which inhibit CYP2C19
Fluvoxamine:
A dose reduction may be considered when combining lansoprazole with the CYP2C19 inhibitor fluvoxamine. A study shows that the plasma concentrations of lansoprazole increase up to 4-fold.
Drugs which induces CYP2C19 and CYP3A4
Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin, and St John's wort (Hypericum_perforatum) can markedly reduce the plasma concentrations of lansoprazole.
Others
Sucralfate/Antacids:
Sucralfate/Antacids may decrease the bioavailability of lansoprazole. Therefore lansoprazole should be taken at least 1 hour after taking these drugs. No clinically significant interactions of lansoprazole with nonsteroidal antiinflammatory drugs have been demonstrated, although no formal interaction studies have been performed.
NSAIDS
No clinically significant interactions of lansoprazole with nonsteroidal antiinflammatory drugs have been demonstrated, although no formal interactions studies have been performed.
4.6 Fertility, Pregnancy and lactation
For lansoprazole no clinical data on exposed pregnancies are available.
Animal studies do not indicate direct or indirect harmful effects with respect to
pregnancy, embryonic/foetal development, parturition or postnatal development.
The use of lansoprazole during pregnancy is not recommended.
It is not known whether lansoprazole is excreted in human breast milk. Animal
studies have shown excretion of lansoprazole in milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with
lansoprazole should be made taking into account the benefit of breast-feeding to the child and the benefit of lansoprazole therapy to the woman.
The use of lansoprazole during breast feeding should be avoided unless considered essential.
4.7 Effects on ability to drive and use machines
Adverse drug reactions such as dizziness, vertigo, visual disturbances and somnolence may occur (see section 4.8). Under these conditions the ability to react may be decreased.
4.8 Undesirable effects
Lansoprazole is well-tolerated, with adverse events generally being mild and transient.
Frequencies are defined as common ( > 1/100, < 1/10); uncommon ( > 1/1,000, < 1/100); rare ( >1/10,000, <1/1,000); very rare ( <1/10,000).
|
Common |
Uncommon |
Rare |
Very rare |
Frequenc y not known | |
|
Blood and lymphatic system disorders |
Thrombocytopenia, eosinophilia, leucopenia |
Anaemia |
Agranulo cytosis, pancytop enia | ||
|
Psychiatric disorders |
Depression |
Insomnia, hallucination, confusion | |||
|
Nervous system disorders |
Headache, dizziness |
Restlessness, vertigo, paresthesia, somnolence, tremor | |||
|
Eye disorders |
Visual |
|
disturbances | |||||
|
Gastrointestinal disorders |
Nausea, diarrhoea, stomach ache, constipation, vomiting, flatulence, dry mouth or throat |
Glossitis, candidiasis of the oesophagus, pancreatitis, taste disturbances |
Colitis, stomatitis | ||
|
Hepatobiliary disorders |
Increase in liver enzyme levels |
Hepatitis, jaundice | |||
|
Skin and subcutaneous tissue disorders |
Urticaria, itching, rash |
Petechiae, purpura, hair loss, erythema multiforme, photosensitivity |
Steven- Johnson syndrome ,toxic epidermal necrolysi s | ||
|
Musculoskeletal and connective tissue disorders |
Arthralgia, myalgia, fracture of the hip, wrist or spine (see section 4.4). | ||||
|
Renal and urinary disorders |
Interstitial nephritis | ||||
|
Reproductive system and breast disorders |
Gynaecomastia | ||||
|
General disorders and administration site conditions |
Fatigue |
Oedema |
Fever, hyperhidrosis, angioedema, anorexia, impotence |
Anaphyla ctic shock | |
|
Investigations |
Increase in cholester ol and triglyceri de levels, hyponatr emia | ||||
|
Metabolism and |
|
nutritional disorders |
hypomagn esaemia. [See Special warnings and precaution s for use (4.4)] |
4.9 Overdose
The effects of overdose on lansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instruction for treatment cannot be given. However, daily doses of up to 180 mg of lansoprazole orally and up to 90 mg of lansoprazole intravenously have been administered in trials without significant undesirable effects.
Please refer to section 4.8 for possible symptoms of lansoprazole overdose. In the case of suspected overdose the patient should be monitored. Lansoprazole is not significantly eliminated by haemodialysis. If necessary, gastric emptying, charcoal and symptomatic therapy is recommended.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC03.
Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H+/K+ATPase causing inhibition of the enzyme activity.
Effect on gastric acid secretion:
Lansoprazole is a specific inhibitor of the parietal cell proton pump. A single oral 30 mg dose of lansoprazole inhibits pentagastrin-stimulated gastric acid secretion by about 80%. After repeated daily administration for seven days, about 90% inhibition of gastric acid secretion is achieved. It has a corresponding effect on the basal secretion of gastric acid. A single oral dose of 30 mg reduces basal secretion by about 70%, and the patients' symptoms are consequently relieved starting from the very first dose. After eight days of repeated administration the reduction is about 85%. A rapid relief of symptoms is obtained by one tablet (30 mg) daily, and most patients with duodenal ulcer recover within 2 weeks, patients with gastric ulcer and reflux oesophagitis within 4 weeks. By reducing gastric acidity, lansoprazole creates an environment in which appropriate antibiotics can be effective against H. pylori.
5.2 Pharmacokinetic properties
Lansoprazole is a racemate of two active enantiomers that are biotransformed into the active form in the acidic environment of the parietal cells. As lansoprazole is rapidly inactivated by gastric acid, it is administered orally in enteric-coated form(s) for systemic absorption.
Absorption
Lansoprazole is rapidly inactivated by gastric acid. Therefore it is formulated as enteric-coated granules in gelatin capsules. Lansoprazole is rapidly absorbed from the duodenum; peak plasma concentrations are achieved within 1.5 - 2.0 hours. Intake of food slows the absorption rate and reduces its bioavailability (AUC) by approximately 50%.
Distribution
The bioavailability after a single lansoprazole 30 mg dose and after repeated daily administration is 80 - 90%. Plasma protein binding is approximately 97%. This has no significant effect on other protein bound active substances.
Metabolism
Lansoprazole is mainly metabolised in the liver.
Lansoprazole is mainly catalysed by the enzyme CYP 2C19. CYP 3A4 also contributes to the metabolism of lansoprazole. CYP 2C19 is subject to genetic polymorphism and approximately 2 - 65 of the general population are termed poor metabolisers (PMs) who are homozygote for a mutant CYP 2C19 allele. PMs lack a functional CYP 2C19 enzyme. In these PMs, exposure of lansoprazole is several-fold higher than in extensive metabolisers.
Three metabolites have been identified in the plasma: the sulfone, 5-hydroxy lansoprazole and the sulfide. These metabolites have a negligible effect on acid secretion.
Excretion
The elimination half-life of lansoprazole is 1.0 - 2.0 hours following single or multiple doses in healthy subjects. There is no evidence of accumulation following multiple doses in healthy subjects. Half life is not changed during repeated dosing of lansoprazole. A single dose of lansoprazole has an inhibitory effect on gastric acid secretion, which lasts for more than 24 hours.
Since lansoprazole is activated in the parietal cells, its plasma concentration is not related to gastric acid secretion.
Three metabolites have been identified in the urine namely: 5-hydroxy sulfone, 5-hydroxy sulphide and 5-hydroxy lansoprazole. These metabolites have very little or no antisecretory activity. A study with 14C labelled lansoprazole indicated that approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the faeces.
In patients with cirrhosis, the AUC of lansoprazole is significantly increased and the elimination half life is prolonged; however, no signs of accumulation have been detected.
The bioavailability of lansoprazole is not significantly changed in patients with renal insufficiency.
Pharmacokinetics in elderly patients:
The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Peak plasma levels were not increased in the elderly. Pharmacokinetics in paediatric patients
The evaluation of the pharmacokinetics in children aged 1 -17 years of age showed a similar exposure as compared to adults with doses of 15 mg for those below 30 kg of weight and 30 mg for those above. The investigation of a dose of 17 mg/m2 body surface or 1 mg/kg body weight also resulted in comparable exposure of lansoprazole in children aged 2-3 months up to one year of age compared to adults.
Higher exposure to lansoprazole in comparison to adults has been seen in infants below the age of 2-3 months with doses of both 1.0 mg/kg and 0.5 mg/kg body weight given as a single dose.
Pharmacokinetics in hepatic insufficiency
The exposure of lansoprazole is doubled in patients with mild hepatic impairment and much more increased in patients with moderate and severe hepatic impairment.
CYP2C19 poor metabolisers
CYP2C19 is subject to genetic polymorphism and 2-6 % of the population, called poor metabolisers (PMs), are homozygote for a mutant CYP2C19 allele and therefore lacks a functional CYP2C19 enzyme. The exposure of lansoprazole is several-fold higher in PMs than in extensive metabolisers (EMs).
5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional
studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction or genotoxicity.
In two rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion. Intestinal metaplasia was also observed, as were Leydig cell hyperplasia and benign Leydig cell tumours. After 18 months of treatment retinal atrophy was observed. This was not seen in monkeys, dogs or mice.
In mouse carcinogenicity studies dose-related gastric ECL cell hyperplasia developed as well as liver tumours and adenoma of rete testis.
The clinical relevance of these findings is unknown.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Capsule Content:
Sugar spheres (sucrose and maize starch)
Sodium starch glycolate Type A
Sodium laurilsulfate
Povidone K30
Potassium oleate
Oleic acid
Hypromellose
Methacrylic acid - ethyl acrylate copolymer 1:1 Triethyl citrate Titanium dioxide (E171)
Talc
Body Composition:
Titanium dioxide (E171)
Gelatin
Cap Composition:
Titanium dioxide (E171)
Gelatin (Limited Bone Gelatin)
Water
Printing Ink:
Shellac (Lacca) Propylene glycol Ammonium hydroxide Potassium hydroxide Black iron oxide (E172)
6.2 Incompatibilities
Not applicable
6.3 Shelf life
2 years.
6.4 Special precautions for storage
Do not store above 30°C.
Store in the original package.
Keep the bottle tightly closed to protect from moisture.
6.5 Nature and contents of container
HDPE bottle, polypropylene cap with integral silica gel desiccant
Packs of 7, 14, 28 or 56 capsules ( 2 x 28 capsules)
Not all pack sizes are marketed.
6.6 Special precautions for disposal
No special instructions
7 MARKETING AUTHORISATION HOLDER
Crescent Pharma Limited
3&4 Quidhampton Business Units
Polhampton Lane
Overton
Hampshire
RG25 3ED
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 20416/0418
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
03/08/2007
10 DATE OF REVISION OF THE TEXT
17/06/2015